bioMérieux S.A. (BMXXY)

Market Cap	16.97B
Revenue (ttm)	4.12B
Net Income (ttm)	447.46M
Shares Out	n/a
EPS (ttm)	3.77
PE Ratio	37.93
Forward PE	27.72
Dividend	0.06 (0.42%)
Ex-Dividend Date	Jun 10, 2025

Volume	350
Average Volume	13,330
Open	13.83
Previous Close	12.95
Day's Range	13.83 - 13.83
52-Week Range	12.95 - 13.83
Beta	0.48
RSI	n/a
Earnings Date	Sep 4, 2025

About Theseus Pharmaceuticals

bioMérieux S.A. develops and markets in vitro diagnostic solutions for infectious diseases in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. It offers CHROMID RANGE, a chromogen culture media; RAPIDEC CARBA NP biochemical test for the detection of carbapenemase producing bacteria; air, surface, and water monitoring systems; BACT/ALERT VIRTUO or 3D, a blood sample culture system; BIOFIRE, a multiplex polymerase chain reaction system; BIOFIRE SPOTFIRE Lowplex PCR point-of-care system; VITEK MS, a mass spectrometry system; VI...

• Industry: Diagnostics & Research
• Sector: Healthcare
• Founded: 1963
• Employees: 14,754
• Stock Exchange: OTCMKTS
• Ticker Symbol: BMXXY

Financial Performance

In 2024, bioMérieux's revenue was 3.98 billion, an increase of 8.31% compared to the previous year's 3.67 billion. Earnings were 432.20 million, an increase of 20.86%.